drugset / Trial / NCT03145948

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

NCT03145948 ↗

Phase 1 Terminated 12 enrolled AbbVie
RandomizedSingle-groupQuadruple-blindOther

Summary

This is a study to assess the pharmacokinetics, safety and tolerability of multiple ascending oral doses of ABBV-553 in healthy volunteers and the pharmacokinetics, safety, tolerability and efficacy of multiple ascending oral doses of ABBV-553 in participants with psoriasis under non-fasting conditions.

Timeline

Start
2017-05-09
Primary completion
2017-08-16
Completion
2017-08-16

Outcome

Outcome not reported

Stopped: “Safety reason”

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-553 Unknown — Oral

Indications